Inhibition of Antibody Secretion by 5-Aminosalicylic Acid

Antioxidant Properties of 5-ASA: Potential Mechanism for Its Anti-Inflammatory Activity

“…A recent report by Mac Dermott et al ( 14) shows that 5-ASA is effecrive at mhibiting mitogenstimulated secretion of immunoglobulins synthesized by peripheral blood and intestinal mononuclear leukocytes. The ICso for 5-ASA in this particular stuJy was approximately 1.0 to 1.35 mM (14). Again, as with the studies nn neutmphil function, the physiological significance of inhibition of leukocyte metabolism and function using high concentrations of sulphasalazine or 5-ASA is, at the present time, not apparent.…”

“…lt has also been determined that high concentrations of sulphasalazme and 5-ASA inhibit the binding of the bacterial peptide, n-formyl-methionylleucyl-phenylalanine (FMLP) to human neutrophils, thereby inhibiting FMLP-induced arthritis in rabbits and FMLP-induced oxygen raJ1cal formation m vitro (13). A recent report by Mac Dermott et al ( 14) shows that 5-ASA is effecrive at mhibiting mitogenstimulated secretion of immunoglobulins synthesized by peripheral blood and intestinal mononuclear leukocytes. The ICso for 5-ASA in this particular stuJy was approximately 1.0 to 1.35 mM (14).…”

Inflammatory Mediators in Inflammatory Bowel Disease

“…Thus, the salicylates have been found to modulate lymphocyte functions (26), inhibit antibody secretion (27), inhibit formation of other inflammatory mediators such as platelet activating factor (28) or cytokines (29) and possess radical scavenging properties (30). lt remains to be elucidated whether the thera-peutic.…”

Progress in understanding the mechanisms of action of 5-aminosalicylic acid

“…Sulfasalazine and 5-ASA inhibit T cell and natural killer cell cytotoxic effector cells (6 -9). 5-ASA also inhibits antibody production by B cells and, therefore, may lead to inhibition of IgG1-induced phagocytosis and cytotoxicity (10). Both sulfasalazine and 5-ASA exert inhibitory effects on macrophage and neutrophil function by impairing chemotaxis and adhesion (11)(12)(13)(14).…”

“…In a study of an American community population with UC, 28% of patients had only a single attack in a median follow-up of 14 yr, 5% had an unremitting course, and the majority, 65%, had an intermittent course (9). In one of the earliest English series evaluating UC, the cumulative probability of a continuously active course was only 1% after 5 yr and 0.1% after 25 yr (10). In a Swedish population-based study of UC by Langholz et al (5), the cumulative probability of a completely relapse-free course was 18% after 5 yr and 11% after 25 yr (5).…”